Ouabain Octahydrate

Suppliers

Names

[ Name ]:
Ouabain Octahydrate

[Synonym ]:
Card-20(22)-enolide, 3-[(6-deoxy-α-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxy-, (1β,3β,5β,11α)-
Ouabain a-L-rhamnoside
G-Strophanthin (JAN)
Strodival
4-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-Tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-{[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2(5H)-furanone
Ouabain
Oubain
(1β,3β,5β,11α)-3-[(6-Deoxy-α-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolid
Gratibain
(1β,3β,5β,11α)-3-[(6-Deoxy-α-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolide
(1b,3b,5b,11a)-3-[(6-Deoxy-a-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolide
Astrobain
OUABAIN OCTAHYDRATE
Purostrophan
EINECS 211-139-3
g-Strophanthin Octahydrate
Card-20(22)-enolide, 3-((6-deoxy-α-L-mannopyranosyl)oxy)-1,5,11,14,19-pentahydroxy-, (1β,3β,5β,11α)-
g-Strophantoside
MFCD00003688
Acocantherin
Gratus strophanthin
STROPHOPERM

Chemical & Physical Properties

[ Density]:
1.5±0.1 g/cm3

[ Boiling Point ]:
838.2±65.0 °C at 760 mmHg

[ Melting Point ]:
260ºC

[ Molecular Formula ]:
C₂₉H₆₀O₂₀

[ Molecular Weight ]:
584.653

[ Flash Point ]:
272.9±27.8 °C

[ Exact Mass ]:
584.283264

[ PSA ]:
280.44000

[ LogP ]:
-1.64

[ Appearance of Characters ]:
powder | white

[ Vapour Pressure ]:
0.0±0.6 mmHg at 25°C

[ Index of Refraction ]:
1.655

[ Water Solubility ]:
H2O: 10 mg/mL cold | Soluble in water.

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: RN3850000

CHEMICAL NAME :: Ouabain octahydrate

CAS REGISTRY NUMBER :: 11018-89-6

LAST UPDATED :: 199409

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C29-H44-O12.8H2-O

MOLECULAR WEIGHT :: 728.89

WISWESSER LINE NOTATION :: L E5 B666TJ A1Q CQ E1 IQ MQ QQ F- DT5OV EHJ& OO- BT6OTJ CQ DQ EQ F1 &QH 8

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1213 ug/kg

TOXIC EFFECTS :: Cardiac - arrhythmias (including changes in conduction)

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 197,19,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 3750 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: JOETD7 Journal of Ethnopharmacology. (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1979- Volume(issue)/page/year: 39,161,1993

Safety Information

[ Symbol ]:

GHS06, GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301 + H331-H373

[ Precautionary Statements ]:
Missing Phrase - N15.00950417-P260-P304 + P340 + P312-P403 + P233

[ Hazard Codes ]:
T: Toxic;

[ Risk Phrases ]:
R23/25

[ Safety Phrases ]:
S45

[ RIDADR ]:
UN 1544 6.1/PG 1

[ WGK Germany ]:
3

[ RTECS ]:
RN3850000

[ Packaging Group ]:
III

[ Hazard Class ]:
6.1(b)

Articles

Crystals of Na(+)/K(+)-ATPase with bound cisplatin.

Biochem. Pharmacol. 92(3) , 494-8, (2014)

Cisplatin is the most widely used chemotherapeutics for cancer treatment, however, its administration is connected to inevitable adverse effects. Previous studies suggested that cisplatin is able to i...

A survey of detergents for the purification of stable, active human cystic fibrosis transmembrane conductance regulator (CFTR).

Biochim. Biophys. Acta 1838(11) , 2825-37, (2014)

Structural knowledge of the cystic fibrosis transmembrane conductance regulator (CFTR) requires developing methods to purify and stabilize this aggregation-prone membrane protein above 1mg/ml. Startin...

Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Biochem. Pharmacol. 90(4) , 367-78, (2014)

Cancer cells often become resistant to chemotherapy through a phenomenon known as multidrug resistance (MDR). Several factors are responsible for the development of MDR, preeminent among them being th...